Salix Receives FDA Marketing Approval for Metozolv ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD

Salix Receives FDA Marketing Approval for Metozolv ODT (Orally
Disintegrating Tablets) for Relief of Diabetic Gastroparesis and
Symptomatic Documented GERD
September 8, 2009
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. today
announced the U.S. Food and Drug Administration (FDA) has granted
marketing approval for Metozolv ODT (metoclopramide HCl) 5mg and 10mg
orally disintegrating tablets. Metozolv ODT is indicated for the
relief of symptoms in adults associated with acute and recurrent
diabetic gastroparesis and for the treatment of short-term therapy
(4-12 weeks) for adults with symptomatic documented gastroesophageal
reflux disease (GERD) who fail